{"filing":{"accession_number":"0001213900-26-078328","cik":"0002079272","ticker":"LABT","company_name":"Lakewood-Amedex Biotherapeutics Inc.","form":"8-K","filing_date":"2026-07-15","report_date":null,"primary_document":"ea0297963-8k_lakewood.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2079272/000121390026078328/ea0297963-8k_lakewood.htm"},"events":[{"id":18143,"run_id":16298,"accession_number":"0001213900-26-078328","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses under Item 7.01 (Regulation FD Disclosure) the availability of a corporate investor presentation detailing the company's development of Bisphosphocin® compounds, lead program Nu-3 for infected diabetic foot ulcers, clinical trial design, regulatory strategy, and upcoming Phase 2 milestones. This is a strategic operational disclosure of clinical development progress and pipeline advancement rather than a routine administrative matter, making it material to investors assessing the company's drug development trajectory and competitive position.","company_name":"Lakewood-Amedex Biotherapeutics Inc.","ticker":"LABT","filing_date":"2026-07-15","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":16862,"accession_number":"0001213900-26-078328","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses under Item 7.01 (Regulation FD Disclosure) the availability of a corporate investor presentation detailing the company's development of Bisphosphocin® compounds, lead program Nu-3 for infected diabetic foot ulcers, clinical trial design, regulatory strategy, and upcoming Phase 2 milestones. This is a strategic operational disclosure of clinical development progress and pipeline advancement rather than a routine administrative matter, making it material to investors assessing the company's drug development trajectory and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:16:40.790363+00:00","company_name":"Lakewood-Amedex Biotherapeutics Inc.","ticker":"LABT","filing_date":"2026-07-15"}]}